Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials
2009 · Cancer · 1,551 citations
https://doi.org/10.1002/cncr.24149
I
Isabelle Ray‐Coquard
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
1.1K
Papers
43.4K
Citations
103
h-index
348
i10-index
Isabelle Ray‐Coquard is an academic researcher from Université Claude Bernard Lyon 1. The author has contributed to research in topics: Ovarian cancer diagnosis and treatment & PARP inhibition in cancer therapy & Sarcoma Diagnosis and Treatment. The author has an h-index of 103, co-authored 899 publications.
ORCID: 0000-0003-2472-8306Papers by this author
worksESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
2019 · Annals of Oncology · 1,101 citations
https://doi.org/10.1093/annonc/mdz062
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
2019 · Annals of Oncology · 1,101 citations
https://doi.org/10.1093/annonc/mdz062
Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure
2009 · European Journal of Cancer · 365 citations
https://doi.org/10.1016/j.ejca.2009.02.011
Initial and Late Resistance to Imatinib in Advanced Gastrointestinal Stromal Tumors Are Predicted by Different Prognostic Factors: A European Organisation for Research and Treatment of Cancer–Italian Sarcoma Group–Australasian Gastrointestinal Trials Group Study
2005 · Journal of Clinical Oncology · 279 citations
https://doi.org/10.1200/jco.2005.11.601
Pazopanib or methotrexate–vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study
2019 · The Lancet Oncology · 194 citations
https://doi.org/10.1016/s1470-2045(19)30276-1
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat